Human VEGF-D (Highly Pure Recombinant)

Description

Human VEGF-D (Highly Pure)
Catalog number: B2010375
Lot number: Batch Dependent
Expiration Date: Batch dependent
Volume/Weight: 10 ug
pH: 7.4 upon reconstitution
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure Human VEGF-D (Highly Pure) expressed in HEK 293. This protein acts as a regulator of both angiogenesis and lymphangiogenesis.
Storage: -20C
Keywords: rHuVEGF-D; Vascular endothelial growth factor D; FIGF
Grade: Biotechnology grade. All components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Stacker SA, Achen MG. Emerging Roles for VEGF-D in Human Disease.
Biomolecules. 2018 Jan 4;8(1):1.

2: Jha SK, Rauniyar K, Chronowska E, Mattonet K, Maina EW, Koistinen H, Stenman
UH, Alitalo K, Jeltsch M. KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D.
Elife. 2019 May 17;8:e44478.

3: Zajkowska M, Lubowicka E, Fiedorowicz W, Szmitkowski M, Jamiołkowski J,
Ławicki S. Human Plasma Levels of VEGF-A, VEGF-C, VEGF-D, their Soluble Receptor
– VEGFR-2 and Applicability of these Parameters as Tumor Markers in the
Diagnostics of Breast Cancer. Pathol Oncol Res. 2019 Oct;25(4):1477-1486.

4: Kong Y, Han J, Wu X, Zeng H, Liu J, Zhang H. VEGF-D: a novel biomarker for
detection of COVID-19 progression. Crit Care. 2020 Jun 23;24(1):373.

5: Desforges M, Rogue A, Pearson N, Rossi C, Olearo E, Forster R, Lees M, Sebire
NJ, Greenwood SL, Sibley CP, David AL, Brownbill P. In Vitro Human Placental
Studies to Support Adenovirus-Mediated VEGF-D^ΔNΔC Maternal Gene
Therapy for the Treatment of Severe Early-Onset Fetal Growth Restriction. Hum
Gene Ther Clin Dev. 2018 Mar;29(1):10-23.

6: Kinashi H, Ito Y, Sun T, Katsuno T, Takei Y. Roles of the TGF-β⁻VEGF-C
Pathway in Fibrosis-Related Lymphangiogenesis. Int J Mol Sci. 2018 Aug
23;19(9):2487.

7: Oplawski M, Dziobek K, Zmarzły N, Grabarek B, Halski T, Januszyk P, Kuś-
Kierach A, Adwent I, Dąbruś D, Kiełbasiński K, Boroń D. Expression Profile of
VEGF-C, VEGF-D, and VEGFR-3 in Different Grades of Endometrial Cancer. Curr
Pharm Biotechnol. 2019;20(12):1004-1010.

8: Sato T, Paquet-Fifield S, Harris NC, Roufail S, Turner DJ, Yuan Y, Zhang YF,
Fox SB, Hibbs ML, Wilkinson-Berka JL, Williams RA, Stacker SA, Sly PD, Achen MG.
VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. J Pathol. 2016
Jun;239(2):152-61.
9: Wada H, Suzuki M, Matsuda M, Ajiro Y, Shinozaki T, Sakagami S, Yonezawa K,
Shimizu M, Funada J, Takenaka T, Morita Y, Nakamura T, Fujimoto K, Matsubara H,
Kato T, Unoki T, Takagi D, Wada K, Wada M, Iguchi M, Masunaga N, Ishii M,
Yamakage H, Kusakabe T, Yasoda A, Shimatsu A, Kotani K, Satoh-Asahara N, Abe M,
Akao M, Hasegawa K; ANOX Study Investigators. Distinct Characteristics of VEGF-D
and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary
Artery Disease. J Am Heart Assoc. 2020 May 5;9(9):e015761.

Products Related to Human VEGF-D (Highly Pure) : Proteins